0 192

Cited 0 times in

No influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B

DC Field Value Language
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박준용-
dc.contributor.author안상훈-
dc.contributor.author이재승-
dc.contributor.author이혜원-
dc.contributor.author장진원-
dc.date.accessioned2022-02-23T01:01:05Z-
dc.date.available2022-02-23T01:01:05Z-
dc.date.issued2021-11-
dc.identifier.issn1352-0504-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187496-
dc.description.abstractThe influence of hepatic steatosis on the natural history of chronic hepatitis B (CHB) virus is unclear. Therefore, we investigated whether concurrent steatosis in patients with CHB influences the probability of hepatitis B surface antigen (HBsAg) loss, fibrosis progression and hepatocellular carcinoma (HCC) development. This study enrolled treatment-naïve patients with virologically (HBV DNA <2,000 IU/ml) and biochemically (alanine aminotransferase level <40 IU/L) quiescent CHB who underwent transient elastography between January 2004 and December 2015 and completed 3 years of follow-up. RESULTS: The mean age of the study population (n = 720) was 52.0 years, and there were more men than women (n = 419, 58.2%). The mean HBV DNA level was 321.6 IU/ml. During the 3-year period, 74 (10.3%) patients achieved HBsAg seroclearance. Lower HBV DNA levels (hazard ratio = 0.995, p < .05) were independently associated with HBsAg seroclearance, while hepatic steatosis was not (p > .05). Fibrosis progressed in 89 (12.4%) patients. Male gender (odds ratio [OR] = 1.720) and higher body mass index (OR = 1.083) were independently associated with an increased probability of fibrosis progression (all p < .05), while higher total cholesterol levels (OR = 0.991) and higher liver stiffness values (OR = 0.862) were independently associated with a decreased probability of fibrosis progression (all p < .05). HCC developed in 46 (6.4%) patients. Male gender (OR = 3.917) and higher AST levels (OR = 1.036) were independently associated with an increased probability of HCC development (p < .05). Hepatic steatosis was not associated with the probability of HBsAg seroclearance, fibrosis progression or HCC development in patients quiescent CHB in our study. Further studies with longer follow-up periods are required to validate our findings.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF VIRAL HEPATITIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular* / epidemiology-
dc.subject.MESHDNA, Viral-
dc.subject.MESHFemale-
dc.subject.MESHHepatitis B Surface Antigens-
dc.subject.MESHHepatitis B virus / genetics-
dc.subject.MESHHepatitis B, Chronic* / complications-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / epidemiology-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.titleNo influence of hepatic steatosis on the 3-year outcomes of patients with quiescent chronic hepatitis B-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJin Won Chang-
dc.contributor.googleauthorJae Seung Lee-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorSeung Up Kim-
dc.identifier.doi10.1111/jvh.13594-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01675-
dc.contributor.localIdA02226-
dc.contributor.localIdA05963-
dc.contributor.localIdA03318-
dc.contributor.localIdA06020-
dc.relation.journalcodeJ01928-
dc.identifier.eissn1365-2893-
dc.identifier.pmid34382730-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/10.1111/jvh.13594-
dc.subject.keywordHepatitis B surface antigen-
dc.subject.keywordhepatocellular carcinoma-
dc.subject.keywordliver fibrosis-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor이재승-
dc.contributor.affiliatedAuthor이혜원-
dc.contributor.affiliatedAuthor장진원-
dc.citation.volume28-
dc.citation.number11-
dc.citation.startPage1545-
dc.citation.endPage1553-
dc.identifier.bibliographicCitationJOURNAL OF VIRAL HEPATITIS, Vol.28(11) : 1545-1553, 2021-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.